Abstract | PURPOSE OF REVIEW: Recent advancements in the understanding of the pathogenesis of large-vessel vasculitis may broaden our currently limited therapeutic possibilities. This review summarizes the available evidence for new treatment strategies in this spectrum of diseases. RECENT FINDINGS: SUMMARY: The possibility of biologic therapy in large vessel vasculitis has emerged. At this time, better delineation of the immunopathogenic mechanisms of this spectrum of diseases and prospective randomized clinical trials are required to move the field forward and decrease the cumulative glucocorticoid toxicity seen in these disorders.
|
Authors | Sebastian Unizony, John H Stone, James R Stone |
Journal | Current opinion in rheumatology
(Curr Opin Rheumatol)
Vol. 25
Issue 1
Pg. 3-9
(Jan 2013)
ISSN: 1531-6963 [Electronic] United States |
PMID | 23114585
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal, Murine-Derived
- Immunologic Factors
- Isoxazoles
- Receptors, Interleukin-6
- Rituximab
- Leflunomide
- tocilizumab
|
Topics |
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Antibodies, Monoclonal, Murine-Derived
(therapeutic use)
- Arteritis
(drug therapy)
- Giant Cell Arteritis
(drug therapy)
- Humans
- Immunologic Factors
(therapeutic use)
- Isoxazoles
(therapeutic use)
- Leflunomide
- Receptors, Interleukin-6
(antagonists & inhibitors)
- Rituximab
- Takayasu Arteritis
(drug therapy)
|